These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

852 related articles for article (PubMed ID: 28356033)

  • 1. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure.
    Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M
    Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
    Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
    Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.
    Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM
    Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.
    Yamagishi S; Fukami K; Matsui T
    Cardiovasc Diabetol; 2015 Jan; 14():2. PubMed ID: 25582643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.
    Neviere R; Yu Y; Wang L; Tessier F; Boulanger E
    Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
    Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
    Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
    Takeuchi M; Takino J; Yamagishi S
    Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical review: The role of advanced glycation end products in progression and complications of diabetes.
    Goh SY; Cooper ME
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1143-52. PubMed ID: 18182449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
    Yamagishi S; Nakamura K; Matsui T; Ueda S; Fukami K; Okuda S
    Expert Opin Investig Drugs; 2008 Jul; 17(7):983-96. PubMed ID: 18549336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy.
    Yoon SJ; Yoon YW; Lee BK; Kwon HM; Hwang KC; Kim M; Chang W; Hong BK; Lee YH; Park SJ; Min PK; Rim SJ
    Exp Mol Med; 2009 Nov; 41(11):802-11. PubMed ID: 19641377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications.
    Wautier JL; Wautier MP; Schmidt AM; Anderson GM; Hori O; Zoukourian C; Capron L; Chappey O; Yan SD; Brett J
    Proc Natl Acad Sci U S A; 1994 Aug; 91(16):7742-6. PubMed ID: 8052654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linking RAGE and Nox in diabetic micro- and macrovascular complications.
    Koulis C; Watson AMD; Gray SP; Jandeleit-Dahm KA
    Diabetes Metab; 2015 Sep; 41(4):272-281. PubMed ID: 26323666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of Advanced Glycation End Products in the Pathogenesis of Diabetic Retinopathy.
    Xu J; Chen LJ; Yu J; Wang HJ; Zhang F; Liu Q; Wu J
    Cell Physiol Biochem; 2018; 48(2):705-717. PubMed ID: 30025404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation.
    Yamagishi SI; Sotokawauchi A; Matsui T
    Mini Rev Med Chem; 2019; 19(13):1040-1048. PubMed ID: 30854960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced glycation endproducts and diabetes. Beyond vascular complications.
    Puddu A; Viviani GL
    Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):132-40. PubMed ID: 21476962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
    Yamagishi S; Matsui T; Nakamura K
    Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end products and reactive oxygen species: uncovering the potential role of ferroptosis in diabetic complications.
    Chen Y; Meng Z; Li Y; Liu S; Hu P; Luo E
    Mol Med; 2024 Sep; 30(1):141. PubMed ID: 39251935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic kidney disease: a role for advanced glycation end-product receptor 1 (AGE-R1)?
    Zhuang A; Forbes JM
    Glycoconj J; 2016 Aug; 33(4):645-52. PubMed ID: 27270766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
    Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
    Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus.
    Lee J; Yun JS; Ko SH
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35956261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.